Ferguson Wellman Capital Management Inc buys $57,286,347 stake in Merck & Co. (MRK)

Merck & Co. (MRK) : Ferguson Wellman Capital Management Inc scooped up 21,281 additional shares in Merck & Co. during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Jul 15, 2016. The investment management firm now holds a total of 970,626 shares of Merck & Co. which is valued at $57,286,347.Merck & Co. makes up approximately 2.33% of Ferguson Wellman Capital Management Inc’s portfolio.

Other Hedge Funds, Including , Hartford Financial Management reduced its stake in MRK by selling 150 shares or 0.52% in the most recent quarter. The Hedge Fund company now holds 28,599 shares of MRK which is valued at $1,705,358. Merck & Co. makes up approx 0.99% of Hartford Financial Management’s portfolio.Gierl Augustine Investment Management Inc boosted its stake in MRK in the latest quarter, The investment management firm added 4 additional shares and now holds a total of 1,055 shares of Merck & Co. which is valued at $62,825. Merck & Co. makes up approx 0.07% of Gierl Augustine Investment Management Inc’s portfolio.Augustine Asset Management Inc reduced its stake in MRK by selling 310 shares or 0.48% in the most recent quarter. The Hedge Fund company now holds 63,631 shares of MRK which is valued at $3,789,226. Merck & Co. makes up approx 2.94% of Augustine Asset Management Inc’s portfolio. Pensionfund Sabic added MRK to its portfolio by purchasing 67,000 company shares during the most recent quarter which is valued at $3,886,000. Merck & Co. makes up approx 1.17% of Pensionfund Sabic’s portfolio.

Merck & Co. closed down -0.61 points or -1.02% at $59.02 with 87,69,171 shares getting traded on Monday. Post opening the session at $59, the shares hit an intraday low of $58.715 and an intraday high of $59.49 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

On the company’s financial health, Merck & Co. reported $0.89 EPS for the quarter, beating the analyst consensus estimate by $ 0.04 according to the earnings call on May 5, 2016. Analyst had a consensus of $0.85. The company had revenue of $9312.00 million for the quarter, compared to analysts expectations of $9445.10 million. The company’s revenue was down -1.2 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.85 EPS.

Merck & Co. Inc. is a global health care company. The Company offers health solutions through its prescription medicines vaccines biologic therapies and animal health products which it markets directly and through its joint ventures. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents generally sold by prescription for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers hospitals government agencies and managed health care providers. The Animal Health segment discovers develops manufactures and markets animal health products including vaccines. The Company’s animal health products are sold to veterinarians distributors and animal producers.

Leave a Reply

Merck & Co. - Is it time to Sell?

Top Brokerage Firms are advising their investors on Merck & Co.. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.